TWI910166B - 幷環化合物及其製備方法、藥物組合物和應用 - Google Patents

幷環化合物及其製備方法、藥物組合物和應用

Info

Publication number
TWI910166B
TWI910166B TW110118416A TW110118416A TWI910166B TW I910166 B TWI910166 B TW I910166B TW 110118416 A TW110118416 A TW 110118416A TW 110118416 A TW110118416 A TW 110118416A TW I910166 B TWI910166 B TW I910166B
Authority
TW
Taiwan
Prior art keywords
alkyl
compound
halogenated
pharmaceutically acceptable
independently selected
Prior art date
Application number
TW110118416A
Other languages
English (en)
Chinese (zh)
Other versions
TW202146402A (zh
Inventor
鄧代國
邱關鵬
王永鋼
雷曾榮
Original Assignee
大陸商廣州費米子科技有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商廣州費米子科技有限責任公司 filed Critical 大陸商廣州費米子科技有限責任公司
Publication of TW202146402A publication Critical patent/TW202146402A/zh
Application granted granted Critical
Publication of TWI910166B publication Critical patent/TWI910166B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW110118416A 2020-05-21 2021-05-21 幷環化合物及其製備方法、藥物組合物和應用 TWI910166B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010433988 2020-05-21
CN202010433988.6 2020-05-21
CN202110529033 2021-05-14
CN202110529033.5 2021-05-14

Publications (2)

Publication Number Publication Date
TW202146402A TW202146402A (zh) 2021-12-16
TWI910166B true TWI910166B (zh) 2026-01-01

Family

ID=78672734

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110118416A TWI910166B (zh) 2020-05-21 2021-05-21 幷環化合物及其製備方法、藥物組合物和應用

Country Status (8)

Country Link
US (1) US20230192683A1 (https=)
EP (1) EP4155305A4 (https=)
JP (1) JP7774312B2 (https=)
KR (1) KR20230015333A (https=)
CN (2) CN115991703A (https=)
AU (1) AU2021276301A1 (https=)
TW (1) TWI910166B (https=)
WO (1) WO2021233427A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI860849B (zh) 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽
KR20240122964A (ko) 2023-02-06 2024-08-13 에이치엘만도 주식회사 피스톤 밸브 조립체 및 이를 구비한 쇼크 업소버
JP2026509366A (ja) 2023-03-10 2026-03-18 イーライ リリー アンド カンパニー Ｓｓｔｒ４アゴニスト及びその塩の調製のための方法
AU2024236692A1 (en) 2023-03-10 2025-10-16 Eli Lilly And Company Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof
WO2024245077A1 (zh) * 2023-05-29 2024-12-05 武汉熙瑞医药科技有限公司 3-氮杂-双环[3.1.0]己烷衍生物、其制备方法及其应用
WO2025096300A1 (en) 2023-10-30 2025-05-08 Eli Lilly And Company Novel methods for the preparation of 3-azabicylco[3.1,0]hexane-6-carboxamide derivatives
CN120965687A (zh) * 2024-05-17 2025-11-18 广州费米子科技有限责任公司 Sstr4激动剂类化合物的晶体形式及其制备方法和用途
WO2025247982A1 (en) 2024-05-29 2025-12-04 Grünenthal GmbH Piperazines which act as sstr4 modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014184275A1 (en) * 2013-05-17 2014-11-20 Boehringer Ingelheim International Gmbh New somatostatin receptor subtype 4 (sstr4) agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2685828A4 (en) * 2011-03-17 2014-08-13 Merck Sharp & Dohme SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS
KR101556318B1 (ko) * 2013-05-15 2015-10-01 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체
EP3045448A4 (en) 2013-09-12 2017-01-25 Sumitomo Chemical Company Limited Nitrogen-containing saturated heterocyclic compound
CN105315293A (zh) * 2014-07-29 2016-02-10 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环化合物及其制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014184275A1 (en) * 2013-05-17 2014-11-20 Boehringer Ingelheim International Gmbh New somatostatin receptor subtype 4 (sstr4) agonists

Also Published As

Publication number Publication date
CN115991703A (zh) 2023-04-21
WO2021233427A1 (zh) 2021-11-25
JP7774312B2 (ja) 2025-11-21
US20230192683A1 (en) 2023-06-22
EP4155305A4 (en) 2024-07-10
TW202146402A (zh) 2021-12-16
EP4155305A1 (en) 2023-03-29
AU2021276301A1 (en) 2023-01-19
JP2023526791A (ja) 2023-06-23
CN113717167B (zh) 2022-12-02
CN113717167A (zh) 2021-11-30
KR20230015333A (ko) 2023-01-31

Similar Documents

Publication Publication Date Title
TWI910166B (zh) 幷環化合物及其製備方法、藥物組合物和應用
TWI910192B (zh) 含氮雜環化合物、藥物組合物和應用
EP4339194A1 (en) Acid addition salt of rock inhibitor, and crystal form, composition and pharmaceutical use thereof
CN113717161B (zh) 含氮饱和杂环化合物及其制备方法、药物组合物和应用
CN118660887A (zh) 三环稠杂环类pde3/4双重抑制及其用途
CN116354936A (zh) 用作选择性aurora a抑制剂的新型杂环化合物
TWI665197B (zh) 具有β２受體激動及Ｍ３受體拮抗活性的苯並環衍生物及其在醫藥上的用途
EP3418277B1 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
JP2025166247A (ja) 化合物の多形体及びその製造方法と使用
CN118496202A (zh) 生长抑制素受体亚型4(sstr4)激动剂
TWI916367B (zh) 含氮飽和雜環化合物及其製備方法、藥物組合物和應用
CN112778274B (zh) 一种含氮杂环衍生物及其制备
HK40062713B (en) Fused-ring compounds, preparation method, pharmaceutical composition and use thereof
HK40062713A (en) Fused-ring compounds, preparation method, pharmaceutical composition and use thereof
EP4620950A1 (en) Piperidine derivative, salt of same, and pharmaceutical composition containing same as active ingredient
TW202604504A (zh) 含氮並環化合物、含其的藥物組合物及其應用
TW202412796A (zh) 五並五員環衍生物的藥物組合物及其在醫藥上的應用
CN119490501A (zh) 咪唑双环化合物及其制备方法和用途
CN117337263A (zh) 作为a2b拮抗剂的含环酰胺的吡啶基黄嘌呤
WO2025148997A1 (zh) 一种四氢吡啶并吡唑衍生物及其在医药上的应用
WO2025067360A1 (zh) 一种DGKzeta拮抗剂及其在医药上的应用
CN119019378A (zh) 一种杂环衍生物及其组合物和药学上的应用
HK40032239B (en) Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof
JP2014012641A (ja) 新規ピリジン誘導体